Dacomitinib/Dacomitinib: a new systemic treatment drug for non-small cell lung cancer

Dacomitinib, a treatment for patients with non-small cell lung cancer carrying classic epidermal growth factor receptor (EGFR) mutations, has been approved for marketing. However, clinical data on its activity against major rare EGFR mutations are currently sparse. It is worth mentioning that dacomitinib is part of systemic treatment. It effectively prevents the growth and spread of tumors by specifically inhibiting tyrosine kinases in tumor cells.

As a common type of cancer, the treatment of non-small cell lung cancer has always attracted much attention. Dacomitinib provides a new and effective treatment for this type of cancer. As a highly effective, irreversible and highly selective second-generation EGFR tyrosine kinase inhibitor (2G EGFR-TKI), dacomitinib can inhibit the signals generated by heterodimers and homodimers formed by all members of the EGFR family.

In the famousARCHER 1050 trial, dacomitinib showed a significantly better effect than gefitinib in terms of progression-free survival (PFS), which provides strong support for it to become the standard first-line treatment for positive advanced non-small cell lung cancer. In addition, a case series study involving 14 patients also showed that dacomitinib also has significant efficacy against central nervous system (CNS) metastasis.

In addition, dacomitinib also shows potential application in patients with rare mutations. Although dacomitinib has shown certain efficacy in the treatment of non-small cell lung cancer, it may also cause some side effects, such as rash, diarrhea, oral ulcers, etc. Therefore, when using dacomitinib for treatment, doctors need to weigh the balance between efficacy and side effects and design an individualized treatment plan based on the patient's specific conditions.